β521

β521 is described in limited public sources as a novel investigational agent reported by Benevira as a potential treatment for COVID-19, with preclinical data suggesting high efficacy in preventing SARS-CoV-2 infection in healthy cells, including against delta and omicron variants, although detailed chemistry, modality, target, and full mechanism of action have not been disclosed. In unrelated academic literature, the designation β521 is also used for a rabbit polyclonal antibody recognizing a C-terminal region of mouse β-dystrobrevin, but this appears to be a research reagent rather than a therapeutic product. Overall, β521 should be considered an early-stage, incompletely characterized experimental agent with insufficient publicly available information to fully define its pharmacology, targets, or clinical development status.

Other names

anti-beta-dystrobrevin antibody β521-Howard Hughes Medical Institute-Dystrobrevin beta-Polyclonal antibody-Therapeutic